Raising the Bar by Lowering the Target
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Clinical Practice Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Stone NJ, et al. Circulation. 2014;129(25 suppl 2):S1-S45.
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report.
Jacobson TA, et al. J Clin Lipidol. 2015;9(2):129-169.
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Lloyd-Jones DM, et al. J Am Coll Cardiol. 2016;68(1):92-125.
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM, et al.J Am Coll Cardiol. 2017;70(14):1785-1822.
Recent Update to the US Cholesterol Treatment Guidelines A Comparison With International Guidelines.
Nayor M, Vasan RS. Circulation. 2016;133(18):1795-1806.
Clinical Assessment Tools
ASCVD Risk Estimator
A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Goff DC, et al. J Am Coll Cardiol. 2014;633(25 Pt B):2935-2959 and Goff DC, et al. Circulation. 2014:129(25 suppl 2):S49-S73).
Reynolds Risk Score
A framework for calculating heart and stroke risk for women and men (Ridker PM, et al. JAMA. 2007;297(6):611-619).
Patient Resources
Centers for Disease Control and Prevention
Educational materials for patients with high cholesterol.
American Heart Association
Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.
The FH Foundation
A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).
Suggested Readings
American College of Cardiology Scientific Sessions & Expo
March 2018; Orlando, Florida.
Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY Outcomes trial.
Steg P, et al. American College of Cardiology Scientific Sessions & Expo; March 2018; Orlando, FL. Late-Breaking Clinical Trial Session 401-08.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
Sabatine MS, et al. Am. Heart J. 2016;173:94-101.
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Goldberg AC, et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8.
Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG. J Manag Care Pharm. 2013;19(2):139-149.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, et al. N Engl J Med. 2015;372(16):1489-1499.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS, et al. N Engl J Med. 2015;372(16):1500-1509.
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
Zhang XL, et al. BMC Med. 2015;13(123):1-18.
From the 2018 American College of Cardiology Scientific Sessions
Module 5
Module 6
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
